State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Shandong Eye Institute, Qingdao, China.
Retina. 2011 Oct;31(9):1791-800. doi: 10.1097/IAE.0b013e31820d3cd2.
To investigate the therapeutic efficacy and optimal drug dose of an intravitreally implantable voriconazole (VCZ) drug delivery system (DDS) in experimental endophthalmitis of Aspergillus fumigatus.
Vitrectomy was performed in albino rabbits with intravitreal inoculation of susceptible A. fumigatus. The animals were randomized into groups of control, polylactic-co-glycolic acid implantation, VCZ injection, and intravitreal VCZ DDS containing 0.5, 0.9, and 1.2 mg of VCZ, respectively. The therapeutic effect was assessed by clinical observation, histology, and microbiology.
The inflammation in the VCZ injection and DDS groups was milder than the untreated and polylactic-co-glycolic acid groups (P ≤ 0.046). The 0.9-mg and 1.2-mg DDS groups presented milder anterior chamber and vitreous inflammation than the injection group during the first 3 weeks (P ≤ 0.044), but only the 1.2-mg DDS group had clearer vitreous thereafter (P ≤ 0.037). Smear and fungal culture showed negative results in all DDS groups. Normal histologic structure of the retina was observed in the eyes recovering from endophthalmitis.
The therapeutic effect of intravitreal VCZ DDS on fungal endophthalmitis appears to be significantly better than intravitreal injection of VCZ. The optimal dose of VCZ in the DDS in this study was 1.2 mg.
研究伏立康唑（VCZ）玻璃体植入型药物输送系统（DDS）治疗烟曲霉菌实验性眼内炎的疗效和最佳药物剂量。
通过玻璃体腔内接种易感烟曲霉菌，在白化兔中进行玻璃体切除术。动物随机分为对照组、聚乳酸-羟基乙酸共聚物植入组、VCZ 注射组和玻璃体腔含 0.5、0.9 和 1.2 mg VCZ 的 VCZ DDS 组。通过临床观察、组织学和微生物学评估治疗效果。
VCZ 注射和 DDS 组的炎症比未治疗组和聚乳酸-羟基乙酸共聚物组轻（P≤0.046）。在前 3 周，0.9 和 1.2 mg DDS 组的眼前房和玻璃体炎症均轻于注射组（P≤0.044），但只有 1.2 mg DDS 组此后的玻璃体更清晰（P≤0.037）。DDS 组的涂片和真菌培养均为阴性。从眼内炎中恢复的眼睛观察到视网膜的正常组织学结构。
玻璃体腔 VCZ DDS 治疗真菌性眼内炎的疗效明显优于 VCZ 玻璃体注射。本研究中 DDS 中 VCZ 的最佳剂量为 1.2 mg。
